Stock RPRX ROYALTY PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
26.62 USD -0.86% Intraday chart for Royalty Pharma plc -2.38% -5.23%
May. 22 Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline MT
May. 16 Transcript : Royalty Pharma plc Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM

Business Summary

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Sales per Business

USD in Million2022Weight2023Weight Delta
Biopharmaceutical Royalties
100.0 %
2,237 100.0 % 2,355 100.0 % +5.24%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
2,237 100.0 % 2,355 100.0 % +5.24%

Managers

Managers TitleAgeSince
Pablo Legorreta CEO
 Chief Executive Officer 60 95-12-31
Terrance Coyne DFI
 Director of Finance/CFO 42 09-12-31
Eric Schneider CTO
 Chief Tech/Sci/R&D Officer - 23-09-20
James Reddoch CTO
 Chief Tech/Sci/R&D Officer 54 08-06-30
Arthur McGivern CIO
 Chief Investment Officer - 22-10-11
Sara Klymkowsky CTO
 Chief Tech/Sci/R&D Officer - 11-12-31
Brienne Kugler CTO
 Chief Tech/Sci/R&D Officer - 13-12-31
George Lloyd CIO
 Chief Investment Officer 64 10-12-31
Christopher Hite BRD
 Director/Board Member 57 20-02-29
George Grofik IRC
 Investor Relations Contact - 19-12-31

Members of the board

Members of the board TitleAgeSince
Rory Riggs FOU
 Founder 71 95-12-31
Errol de Souza BRD
 Director/Board Member 70 20-05-31
David Hodgson BRD
 Director/Board Member 67 22-06-22
Ted Love BRD
 Director/Board Member 65 20-07-29
Henry Fernandez BRD
 Director/Board Member 65 20-07-29
Gregory Norden BRD
 Director/Board Member 66 20-02-10
Pablo Legorreta CEO
 Chief Executive Officer 60 95-12-31
Mario Giuliani BRD
 Director/Board Member 52 20-05-31
Bonnie Bassler BRD
 Director/Board Member 61 20-06-15
Christopher Hite BRD
 Director/Board Member 57 20-02-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 50,000 0 0 85.52 %
Stock B 1 146,456,241 0 0
Stock C 1 450,981,030 385,668,432 ( 85.52 %) 0

Shareholders

NameEquities%Valuation
Eaton Vance Management
9.899 %
44,217,885 9.899 % 1 243 M $
Nogra Group SICAF-SIF SA
9.772 %
43,651,170 9.772 % 1 227 M $
Vanguard Fiduciary Trust Co.
8.440 %
37,699,682 8.440 % 1 060 M $
Fidelity Management & Research Co. LLC
7.528 %
33,625,688 7.528 % 945 M $
BlackRock Advisors LLC
3.916 %
17,492,523 3.916 % 492 M $
Baillie Gifford & Co.
3.730 %
16,662,792 3.730 % 468 M $
Viking Global Investors LP
2.571 %
11,485,547 2.571 % 323 M $
Adage Capital Partners GP LLC
2.422 %
10,816,931 2.422 % 304 M $
Mario Giuliani
2.311 %
10,322,592 2.311 % 290 M $
STATE STREET CORPORATION
2.037 %
9,100,148 2.037 % 256 M $
NameEquities%Valuation
Pablo Legorreta
30.72 %
74,095,660 30.72 % 2 083 M $
General Atlantic LLC
10.26 %
24,743,870 10.26 % 696 M $
George Lloyd
3.189 %
7,691,520 3.189 % 216 M $
Terrance Coyne
2.686 %
6,478,180 2.686 % 182 M $
Rory Riggs
1.119 %
2,700,000 1.119 % 76 M $
Marshall Urist
0.9684 %
2,335,940 0.9684 % 66 M $
Christopher Hite
0.6079 %
1,466,410 0.6079 % 41 M $
Errol de Souza
0.2073 %
500,140 0.2073 % 14 M $
Henry Fernandez
0.1613 %
389,130 0.1613 % 11 M $
Gregory Norden
0.0600 %
144,660 0.0600 % 4 M $

Company contact information

Royalty Pharma Plc

110 East 59th Street 33rd floor

10022, New York

+212 883 0200

http://www.royaltypharma.com
address Royalty Pharma plc(RPRX)

Group companies

NameCategory and Sector
Royalty Pharma Holdings Ltd.
Logo Royalty Pharma Holdings Ltd.

Royalty Pharma Holdings Ltd.

Financial ConglomeratesFinance

Royalty Pharma Holdings Ltd. operates as an investment holding company. The company was founded on February 10, 2020 and is headquartered in Bristol, the United Kingdom.

Financial Conglomerates

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Royalty Pharma plc

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
26.62 USD
Average target price
45.75 USD
Spread / Average Target
+71.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ROYALTY PHARMA PLC Stock Royalty Pharma plc
-5.23% 12.01B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.09% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RPRX Stock
  4. Company Royalty Pharma plc